for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

109.18USD

Change

10.62(+10.78%)

Volume

25,850,691

Today's Range

98.65

 - 

109.29

52 Week Range

17.68

 - 

109.29

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
98.56
Open
99.03
Volume
25,850,691
3M AVG Volume
230.31
Today's High
109.29
Today's Low
98.65
52 Week High
109.29
52 Week Low
17.68
Shares Out (MIL)
395.71
Market Cap (MIL)
43,203.63
Forward P/E
-56.09
Dividend (Yield %)
--

Next Event

Moderna Inc at Piper Sandler Healthcare Conference (Virtual)

Latest Developments

More

Moderna Announces The European Commission's Approval Of Advance Purchase Agreement For Initial 80 Million Doses Of COVID-19 Vaccine

Moderna’S Covid-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint In The First Interim Analysis Of The Phase 3 Cove Study

Moderna Has Completed Case Accrual For First Planned Interim Analysis Of Its Vaccine Against Covid-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resource Officer

Key Stats

2.29 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020(E)

0.4K
EPS (USD)

2018

-4.950

2019

-1.550

2020(E)

-1.768
Price To Earnings (TTM)
--
Price To Sales (TTM)
175.12
Price To Book (MRQ)
15.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.94
LT Debt To Equity (MRQ)
3.94
Return on Investment (TTM)
-25.87
Return on Equity (TTM)
-19.15

Latest News

Latest News

Explainer-When and how will COVID-19 vaccines become available?

Pfizer Inc with partner BioNTech SE and Moderna Inc have released trial data showing their COVID-19 vaccines to be about 95% effective at preventing the illness, while AstraZeneca Plc this week said its vaccine could be up to 90% effective.

When and which COVID-19 vaccines are likely to be available in Asia

Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc have released trial data this month showing their experimental vaccines are effective in preventing the disease. If regulators approve any of the vaccines in coming weeks, the companies have said distribution...

Latest on worldwide spread of the coronavirus

Countries around the world agonised over new coronavirus curbs ahead of Christmas and other holidays as global infections crossed 60 million and U.S. officials pleaded with Americans to stay home over Thanksgiving.

Recipharm to produce some of Moderna's COVID-19 vaccine in France

Sweden's Recipharm will produce doses of Moderna's COVID-19 vaccine candidate in central France, the company said on Wednesday, adding it had started recruiting and investing to start manufacturing.

EU secures 160 million doses of Moderna's COVID-19 vaccine

The European Union has struck a deal for up to 160 million doses of U.S. firm Moderna's COVID-19 vaccine candidate, the head of the European Commission said on Tuesday, taking the EU's potential stock of COVID-19 shots to nearly 2 billion.

EU has deal with Moderna for supply of COVID-19 vaccine candidate- von der Leyen

The European Union has reached a deal with U.S. biotech firm Moderna for the supply of up to 160 million doses of its COVID-19 vaccine candidate, the president of the European Commission said on Tuesday.

EU drug regulator could rule on COVID-19 vaccines by year end - report

The European Medicines Agency (EMA) could produce a scientific opinion on COVID-19 vaccines seeking regulatory approval by the end of the year in a best case scenario, the regulator's new chief was quoted as saying on Tuesday.

Sweden's Recipharm signs deal to package Moderna's COVID-19 vaccine

Swedish pharmaceuticals maker Recipharm said on Tuesday it had agreed a preliminary deal with Moderna Inc to fill and seal the packaging for the U.S drugmaker's new COVID-19 vaccine.

Encouraging Oxford vaccine results keep Britain on track for spring roll-out

Britain is on track to make COVID-19 vaccines widely available by next spring after the shot developed by Oxford University and AstraZeneca was up to 90% effective in trials, the head of the university's Jenner Institute told Reuters on Monday.

Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus

The experimental COVID-19 vaccine developed by AstraZeneca and Oxford University would have a higher efficacy rate if trials were only measuring whether the shot prevents hospitalisation and severe disease, Oxford's vaccine chief said on Monday.

Moderna to charge $25-$37 for COVID-19 vaccine: CEO tells paper

Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

Hedge funds sold Moderna, BioNtech shares before vaccine news

A number of hedge funds sold positions in two drug companies leading the race to a coronavirus vaccine in the quarter before both announced breakthroughs that lifted their stock prices, while a few took stakes in the companies during that time.

Pfizer, Moderna COVID-19 vaccines may be authorized for use within weeks: U.S. official

COVID-19 vaccines from Pfizer Inc and Moderna Inc could be ready for U.S. authorization and distribution within weeks, setting the stage for inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said on Wednesday.

Pfizer, Moderna COVID-19 vaccines may be ready for U.S. authorization within weeks: U.S. official

Pfizer Inc's and Moderna Inc's COVID-19 vaccine candidates could be ready for U.S. authorization and distribution within weeks, setting the stage for widespread inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said during a press...

Air France-KLM prepares COVID-19 vaccine airlift

Air France-KLM is among airlines gearing up for the challenge of transporting millions of doses of temperature-sensitive COVID-19 vaccines in the midst of a travel slump.

Stocks ascend to record on economic recovery, vaccine outlook

(This Nov. 16 story corrects spelling and location of 6 Meridian)

Airlines scramble to prepare for ultra-cold COVID-19 vaccine distribution

Airlines are scrambling to prepare ultra-cold shipping and storage facilities to transport COVID-19 vaccines developed by Pfizer and Moderna, whose doses, which require deep freezing, are likely to be among the first to be distributed.

Hong Kong shares end higher on vaccine hopes, stronger automakers

Hong Kong stocks ended higher for a third straight session on Wednesday, with the automotive sector leading gains, as investors continued to cheer news of COVID-19 vaccine breakthroughs.

Nifty, Sensex flat as investors book gains after record highs

Indian shares were little changed on Wednesday as investors locked in gains after a record-setting rally, and surging coronavirus cases globally took the focus away from upbeat vaccine trial results.

Global stocks slip from record as investors gauge vaccine hope with virus concern

A gauge of global stocks edged lower from a record on Tuesday, as rising coronavirus cases raised concerns about fresh lockdown measures and tamped down recent optimism over promising vaccine trial results.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up